PMID- 35744019
OWN - NLM
STAT- MEDLINE
DCOM- 20220627
LR  - 20240102
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 58
IP  - 6
DP  - 2022 Jun 1
TI  - Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, 
      Radiological and NAT Regimen Prognostic Factors-Literature Review.
LID - 10.3390/medicina58060756 [doi]
LID - 756
AB  - Background and Objectives: Pancreatic ductal adenocarcinoma (PDAC) remains one of 
      the most lethal tumors, with a 5-year overall survival rate of less than 10%. To 
      date, curative surgical resection remains the only favorable option for improving 
      patients' survival. However, there is no consensus on which prognostic 
      biochemical, radiological markers or neoadjuvant therapy regimens would benefit 
      patients the most. Materials and Methods: A literature review was performed 
      focusing on overall survival, R0 resection, 30-day mortality, adverse events 
      (AEs), and elevated biomarkers. The electronic databases were searched from 2015 
      to 2020. Results: We reviewed 22 independent studies. In total, 20 studies were 
      retrospective single- or multi-center reviews, while 2 studies were prospective 
      Phase II trials. Conclusions: Patients with borderline resectable or locally 
      advanced PDAC, who received neoadjuvant therapy (NAT) and surgery, have 
      significantly better survival rates. The CA 19-9 biomarker levels in the 
      neoadjuvant setting should be evaluated and considered as a specific biomarker 
      for tumor resectability and overall survival.
FAU - Gulla, Aiste
AU  - Gulla A
AD  - Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.
AD  - Department of Surgery, Institute of Clinical Medicine, Faculty of Medicine, 
      Vilnius University, Vilnius University Hospital Santaros klinikos, 08410 Vilnius, 
      Lithuania.
AD  - Department of Surgery, Georgetown University Hospital, Washington, DC 20007, USA.
FAU - Hashimoto, Daisuke
AU  - Hashimoto D
AUID- ORCID: 0000-0002-7880-889X
AD  - Department of Surgery, Kansai Medical University, Hirakata 573-1191, Japan.
FAU - Wagner, Doris
AU  - Wagner D
AD  - Department of Visceral, General and Transplantation Surgery, University of Graz, 
      3, 8010 Graz, Austria.
FAU - Damaseviciute, Ryte
AU  - Damaseviciute R
AD  - Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.
FAU - Strupas, Kestutis
AU  - Strupas K
AD  - Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.
AD  - Department of Surgery, Institute of Clinical Medicine, Faculty of Medicine, 
      Vilnius University, Vilnius University Hospital Santaros klinikos, 08410 Vilnius, 
      Lithuania.
FAU - Satoi, Sohei
AU  - Satoi S
AUID- ORCID: 0000-0001-6527-5409
AD  - Department of Surgery, Kansai Medical University, Hirakata 573-1191, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220601
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - *Carcinoma, Pancreatic Ductal/drug therapy/pathology/surgery
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Pancreatectomy
MH  - *Pancreatic Neoplasms/drug therapy
MH  - Prognosis
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC9227260
OTO - NOTNLM
OT  - neoadjuvant treatment
OT  - pancreatic adenocarcinoma
OT  - surgical resectability
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/28 06:00
PMCR- 2022/06/01
CRDT- 2022/06/24 01:27
PHST- 2022/04/29 00:00 [received]
PHST- 2022/05/27 00:00 [revised]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/06/24 01:27 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/28 06:00 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - medicina58060756 [pii]
AID - medicina-58-00756 [pii]
AID - 10.3390/medicina58060756 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2022 Jun 1;58(6):756. doi: 10.3390/medicina58060756.